Traders should monitor for upcoming earnings or clinical trial updates, as this level of coordinated insider selling may suggest lack of confidence in near-term catalysts. Watch for Form 4 filings to confirm whether these were pre-arranged 10b5-1 plans or discretionary trades.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 23 $7.43entry
- T+1 · 9mo ago +27.73%α +26.99% · $9.49
- T+5 · 9mo ago +25.71%α +25.09% · $9.34
- T+20 · 8mo ago +18.98%α +22.92% · $8.84
- T+60 · 6mo ago +18.04%α +9.78% · $8.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at Vir Biotechnology, including the CEO, CMO, and General Counsel, sold shares worth over $191K in the past week. These sales follow a pattern of insider selling in the last 30 days and involve material dollar amounts, though they are not accompanied by any public financial disclosures or news that would explain the timing.
Key Financial Metrics
Key Facts
- CEO Marianne De Backer sold $141,894 worth of shares in a single transaction on February 23, 2026.
- EVP Vanina de Verneuil and CMO Mark Eisner also sold $33,128 and $15,569 worth of shares, respectively, on the same day.
- All three insiders also had option awards (A) totaling 138,000 shares on February 22, which were granted at $0, indicating a routine award or exercise unrelated to trading activity.
- No insider purchases were reported in the cluster, only sales by top executives.
- Recent insider activity over the past 30 days includes three additional sells totaling $191K, showing a consistent trend of insider divestment.
Financial Impact
Total insider sales: $191K in the past 7 days, all from senior executives.
Risk Factors
- Insider selling could signal negative non-public information, especially when concentrated among C-suite executives.
- Potential for negative sentiment impact ahead of earnings or clinical data readouts if no positive catalyst emerges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-VIR-1771978337169 |
Track record
36 reports on VIR
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers